Westlake posts $782 million Q3 net loss on $727 million chlorovinyls goodwill impairment
Westlake reported a third-quarter 2025 net loss of $782 million, or $6.06 per share, including a non-cash $727 million charge to write off all goodwill tied to its North American Chlorovinyls unit. Excluding identified items, the net loss was $38 million, or $0.29 per share, compared with net income of $108 million, or $0.83 per share, a year earlier. Shareholders face weaker sales and profit, and the company says cost savings and a plant shutdown should help margins in 2026.
Key points
- Net sales were $2.8 billion, down from $3.1 billion in the third quarter of 2024.
- EBITDA excluding identified items was $313 million, compared with $580 million a year earlier.
- Identified items included the $727 million goodwill impairment and $17 million of accrued shutdown expenses.
- Management expects about $200 million of cost savings in 2026 and about $100 million of annual losses removed from the Pernis shutdown starting in 2026.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.